MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma-Reference-Cited by-同舟云学术

MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Published:2017-02-15 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Mikamori Manabu,Yamada Daisaku,Eguchi Hidetoshi,Hasegawa Shinichiro,Kishimoto Tomoya,Tomimaru Yoshito,Asaoka Tadafumi,Noda Takehiro,Wada Hiroshi,Kawamoto Koichi,Gotoh Kunihito,Takeda Yutaka,Tanemura Masahiro,Mori Masaki,Doki Yuichiro

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep42339.pdf

Reference52 articles.

1. Vincent, A., Herman, J., Schulick, R., Hruban, R. H. & Goggins, M. Pancreatic cancer. Lancet. 378, 607–620 (2011).

2. Okazaki, T. et al. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cnacer Res. 14, 2042–2048 (2008).

3. Mizuguchi, T. et al. Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? Surg Today. 46, 139–148 (2016).

4. Arima, K. et al. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Surg Today 46, 792–797 (2016).

5. Oettle, H. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA. 297, 267–277 (2007).

Cited by 214 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MLH1 Inhibits Metastatic Potential of Pancreatic Ductal Adenocarcinoma via Downregulation of GPRC5C;Laboratory Investigation;2024-09

2. Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network analysis;Pancreatology;2024-09

3. Bladder cancer: non-coding RNAs and exosomal non-coding RNAs;Functional & Integrative Genomics;2024-08-31

4. Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer;Molecular Cancer;2024-08-02

5. MiR-155 -targeted IcosL controls tumor rejection;Proceedings of the National Academy of Sciences;2024-07-09